Effects of Race and Gender Classifications on Atherosclerotic Cardiovascular Disease Risk Estimates for Clinical Decision-Making in a Cohort of Black Transgender Women - PubMed
- ️Sun Jan 01 2023
. 2023 Nov 30;7(1):803-808.
doi: 10.1089/heq.2023.0066. eCollection 2023.
Elle Lett 2 3 4 , Ashleigh J Rich 1 , Huijun Jiang 5 , Andrea L Wirtz 6 , Asa Radix 7 , Sari L Reisner 8 9 10 11 , Alexander B Harris 7 , Jowanna Malone 12 , William G La Cava 2 13 , Catherine R Lesko 6 , Kenneth H Mayer 9 11 14 , Carl G Streed Jr 11 15 16
Affiliations
- PMID: 38076214
- PMCID: PMC10698798
- DOI: 10.1089/heq.2023.0066
Effects of Race and Gender Classifications on Atherosclerotic Cardiovascular Disease Risk Estimates for Clinical Decision-Making in a Cohort of Black Transgender Women
Tonia Poteat et al. Health Equity. 2023.
Abstract
Introduction: Despite their dynamic, socially constructed, and imprecise nature, both race and gender are included in common risk calculators used for clinical decision-making about statin therapy for atherosclerotic cardiovascular disease (ASCVD) prevention.
Methods and materials: We assessed the effect of manipulating six different race-gender categories on ASCVD risk scores among 90 Black transgender women.
Results: Risk scores varied by operationalization of race and gender and affected the proportion for whom statins were recommended.
Discussion: Race and gender are social constructs underpinning racialized and gendered health inequities. Their rote use in ASCVD risk calculators may reinforce and perpetuate existing inequities.
Keywords: African American; cardiovascular risk calculator; statin; transgender.
© Tonia Poteat et al., 2023; Published by Mary Ann Liebert, Inc.
Conflict of interest statement
T.P. and A.L.W. receive research funding from ViiV Healthcare to their research institutes unrelated to this work. C.G.S. receives consulting fees from EverlyWell, L'Oreal, and the Texas Health Institute unrelated to this work.
Similar articles
-
Borja-Hart N, Graff JC, Nolan VG, Wang J, Cooper-DeHoff RM, Ancheta IB. Borja-Hart N, et al. J Clin Pharm Ther. 2019 Aug;44(4):632-639. doi: 10.1111/jcpt.12837. Epub 2019 Apr 8. J Clin Pharm Ther. 2019. PMID: 30963623
-
Yao X, Shah ND, Gersh BJ, Lopez-Jimenez F, Noseworthy PA. Yao X, et al. JAMA Netw Open. 2020 Nov 2;3(11):e2025505. doi: 10.1001/jamanetworkopen.2020.25505. JAMA Netw Open. 2020. PMID: 33216139 Free PMC article.
-
Jackson EA, Ruppert K, Derby CA, Lian Y, Chae CU, Kazlauskaite R, Neal-Perry G, El Khoudary SR, Harlow SD, Solomon DH. Jackson EA, et al. Clin Cardiol. 2020 Dec;43(12):1388-1397. doi: 10.1002/clc.23448. Epub 2020 Aug 30. Clin Cardiol. 2020. PMID: 32862481 Free PMC article.
-
Emami H, Takx RAP, Mayrhofer T, Janjua S, Park J, Pursnani A, Tawakol A, Lu MT, Ferencik M, Hoffmann U. Emami H, et al. JACC Cardiovasc Imaging. 2017 Sep;10(9):1031-1038. doi: 10.1016/j.jcmg.2016.10.022. Epub 2017 Mar 15. JACC Cardiovasc Imaging. 2017. PMID: 28330658 Free PMC article. Review.
Cited by
-
Dale SK, Willie PR, Nalule EK, Lewis C, Heard S, Gardner N, Warman C, Palmer K, Wyatt B, Benoit P. Dale SK, et al. BMC Public Health. 2024 Nov 19;24(1):3212. doi: 10.1186/s12889-024-20717-0. BMC Public Health. 2024. PMID: 39563283 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Leading Causes of Death. 2022. Available from: https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm [Last accessed: February 27, 2023].
-
- Gao Z, Chen Z, Sun A, et al. . Gender differences in cardiovascular disease. Med Novel Technol Dev 2019;4:100025; doi: 10.1016/j.medntd.2019.100025. - DOI
LinkOut - more resources
Full Text Sources